156549-71-2

Upstream product

• 156580-71-1 6,3'-anhydro-3-chloro-1-(2-deoxy-5-O-triphenylmethyl-β-D-threo-pentofuranosyl)pyridazin-4-on7 
• 76-83-5 trityl chloride 
• 87008-98-8 3-chloro-4-methoxy-1-(2-deoxy-β-D-erythro-pentofuranosyl)pyridazin-6-one 
• 156549-65-4 3-chloro-4-methoxy-1-<2-deoxy-3,5-bis(methylsulfonyl)-β-D-erythro-pentofuranosyl>pyridazin-6-one 
• 156549-64-3 3-chloro-4-methoxy-1-(2-deoxy-5-O-triphenylmethyl-β-D-erythro-pentofuranosyl)pyridazin-6-one 
• 156549-67-6 3-chloro-4-methoxy-1-(2-deoxy-3-O-p-toluenesulfonyl-5-O-triphenylmethyl-β-D-erythro-pentofuranosyl)pyridazin-6-one 
• 156549-68-7 3-chloro-4-methyl-1-(2-deoxy-3-O-methanesulfonyl-5-O-triphenylmethyl-β-D-erythro-pentofuranosyl)pyridazin-6-one 

Relevant academic research and scientific papers

Synthesis of 2',3'-dideoxy- and 3'-azido-2',3'-dideoxy-pyridazine nucleosides as potential antiviral agents

The synthesis of 4-methoxy-, 4-amino-3-chloro-, and 4-amino-1-(2,3- dideoxy-β-D-glycero-pentofuranosyl)pyridazin-6-one nucleosides, 6, 19 and 20 is described. The synthesis of 3,4-dichloropyridazin-6-one (10) was accomplished in 44% overall yield using bromomaleic anhydride (17) as the starting material. The condensation of the silylated base of 10 with the halogenose 12 in the presence of trimethylsilyl triflate as a catalyst afforded a mixture of 3,4-dichloro-1-(3,5-di-O-p-toluoyl-2-deoxy-β-D- erythro-pentofuranosyl)pyridazin-6-one (13) in 67% and its α-anomer 14 in 12% yield, respectively. A series of 3'-sulfonate esters were prepared to explore the synthesis of 3-chloro-4-hydroxy-1-(3-azido-2,3-dideoxy-β-D- erythro-pentofuranosyl)pyridazin-6-one (32) via 6,3-anhydronucleoside analogues. Compounds 15, 19 and 20 were evaluated against human immunodeficiency virus, human cytomegalovirus, and herpes simplex virus type 1 but were inactive.